IP Library › Granted Patent US 12,358,979
Granted Patent B2
US 12,358,979 · App. 18/979,795 · Granted Jul 15, 2025

Antibodies that bind interleukin 13 and methods of use

Inventors: Hussam H. Shaheen (Waltham, MA); Kenneth Evan Thompson (Waltham, MA); Peter Harwin (Waltham, MA); Tomas Kiselak (Waltham, MA)
Assignee: Apogee Therapeutics, Inc.
C07K16/244A61K2039/505C07K2317/24C07K2317/76C07K2317/92C07K2317/94
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,358,979
App. No.
18/979,795
Granted
Jul 15, 2025
Kind
B2
Abstract

Described herein are novel and improved antibodies that bind Interleukin 13 (IL-13) and methods of use thereof. In certain aspects, described herein are methods of inhibiting IL-13 biological activity. In certain aspects, described herein are pharmaceutical compositions comprising the anti-IL-13 antibodies. In certain aspects, the antibodies and methods described herein are used for treatment of an inflammatory disease or disorder associated with elevated levels of IL-13 and/or IgE.

Claims (28)

1. An isolated antibody that binds Interleukin 13 (IL-13), wherein the antibody comprises

a heavy chain variable region sequence set forth in SEQ ID NO: 3 and

a light chain variable region sequence set forth in SEQ ID NO: 39, and

wherein the antibody comprises a human IgG1 Fc region with LALA and/or YTE mutations.

2. The isolated antibody of claim 1 , wherein the antibody is a humanized or chimeric antibody.

3. The isolated antibody of claim 2 , wherein the antibody is a humanized antibody.

4. The isolated antibody of claim 1 , wherein the antibody is a monoclonal antibody.

5. The isolated antibody of claim 1 , wherein the antibody binds an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473.

6. The isolated antibody of claim 1 , wherein the antibody binds to an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473 with a K D of less than or equal to about 1, 2, 3, 4, 5, 6, 7, 8, or 9×10 −9 M, as measured by surface plasmon resonance (SPR).

7. The isolated antibody of claim 1 , wherein the antibody binds to an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473 with a K D of less than or equal to about 1×10 −10 M, as measured by SPR.

8. The isolated antibody of claim 1 , wherein the antibody binds to human IL-13 with a K D of less than or equal to about 1×10 −9 M, as measured by SPR.

9. The isolated antibody of claim 1 , wherein the antibody is formulated for subcutaneous injection.

10. The isolated antibody of claim 1 , wherein the antibody is formulated for intravenous injection.

11. A composition comprising the isolated antibody of claim 1 and a pharmaceutically acceptable excipient.

12. A kit comprising:

(a) the isolated antibody that binds IL-13 of claim 1 ; and

(b) instructions for use.

13. The isolated antibody of claim 1 , wherein the antibody comprises a human IgG1 Fc region with LALA and YTE mutations.

14. The isolated antibody of claim 1 , wherein the antibody comprises a human IgG1 Fc region with YTE mutations.

15. An isolated antibody that binds IL-13, wherein the antibody comprises

a heavy chain variable region sequence set forth in SEQ ID NO: 3 and

a light chain variable region sequence set forth in SEQ ID NO: 39.

16. The isolated antibody of claim 15 , wherein the antibody comprises a human IgG1 Fc region.

17. The isolated antibody of claim 15 , wherein the antibody binds to an IL-13 sequence set forth in SEQ ID NO: 472 or SEQ ID NO: 473 with a K D of less than or equal to about 1×10 −10 M, as measured by SPR.

18. The isolated antibody of claim 17 , wherein the antibody comprises a human IgG1 Fe region with LALA and YTE mutations.

19. An isolated antibody that binds IL-13, wherein the antibody comprises a heavy chain variable region sequence set forth in SEQ ID NO: 3, a light chain variable region sequence set forth in SEQ ID NO: 39, a constant heavy chain sequence set forth in SEQ ID NO: 439, and a constant light chain sequence set forth in SEQ ID NO: 469.

20. The isolated antibody of claim 19 , wherein the antibody is formulated for subcutaneous injection.

21. A composition comprising the isolated antibody of claim 19 and a pharmaceutically acceptable excipient.

Assignments (11)
SECURITY INTEREST Recorded May 27, 2026
From: APOGEE THERAPEUTICS, INC.
To: ANNAPURNA AGGREGATOR L.P.
Reel/Frame 074776/0294 →
CORRECTIVE ASSIGNMENT TO CORRECT THE 4TH INVENTOR'S FIRST NAME PREVIOUSLY RECORDED ON REEL 71117 FRAME 197. ASSIGNOR(S) HEREBY CONFIRMS THE THE CORRECTION WITH EXECUTED ASSIGNMENT.. Recorded May 19, 2025
From: SHAHEEN, HUSSAM H.; THOMPSON, KENNETH EVAN; HARWIN, PETER; KISELAK, TOMAS
To: PARAGON THERAPEUTICS, INC.
Reel/Frame 071293/0027 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: PARAGON THERAPEUTICS, INC.
To: APOGEE BIOLOGICS, INC.
Reel/Frame 071117/0252 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: SHAHEEN, HUSSAM H.; THOMPSON, KENNETH EVAN; HARWIN, PETER; KISELAK, TOMAS
To: PARAGON THERAPEUTICS, INC.
Reel/Frame 071117/0270 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: PARAGON THERAPEUTICS, INC.
To: APOGEE BIOLOGICS, INC.
Reel/Frame 071117/0347 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: SHAHEEN, HUSSAM H.; THOMPSON, KENNETH EVAN; HARWIN, PETER; KISELAK, TOMANS
To: PARAGON THERAPEUTICS, INC.
Reel/Frame 071117/0197 →
MERGER Recorded May 14, 2025
From: APOGEE BIOLOGICS, INC.
To: APOGEE THERAPEUTICS, INC.
Reel/Frame 071117/0359 →
CHANGE OF NAME Recorded May 14, 2025
From: APOGEE THERAPEUTICS, INC.
To: APOGEE BIOLOGICS, INC.
Reel/Frame 071279/0595 →
CONFIRMATORY ASSIGNMENT Recorded May 14, 2025
From: PARAGON THERAPEUTICS, INC.
To: APOGEE THERAPEUTICS, INC.
Reel/Frame 071279/0755 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: SHAHEEN, HUSSAM H.; THOMPSON, KENNETH EVAN; HARWIN, PETER; KISELAK, TOMAS
To: PARAGON THERAPEUTICS, INC.
Reel/Frame 071117/0350 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 14, 2025
From: PARAGON THERAPEUTICS, INC.
To: APOGEE THERAPEUTICS, INC.
Reel/Frame 071117/0219 →
Continuity (5)
Continuation PCTUS2023068621 · Jun 16, 2023
Provisional Application 63469167 · May 26, 2023
Provisional Application 63462822 · Apr 28, 2023
Provisional Application 63353367 · Jun 17, 2022
Related Publication 20250129150A1 · Apr 24, 2025
References Cited (118)
US 7615213B2 · Kasaian et al. · 2009 [cited by applicant]
US 7674459B2 · Fung et al. · 2010 [cited by applicant]
US 7863426B2 · Wan et al. · 2011 [cited by applicant]
US 8067199B2 · Fung et al. · 2011 [cited by applicant]
US 8088618B2 · Fung et al. · 2012 [cited by applicant]
US 8221752B2 · Kasaian et al. · 2012 [cited by applicant]
US 8318160B2 · Fung et al. · 2012 [cited by applicant]
US 8734797B2 · Fung et al. · 2014 [cited by applicant]
US 8734801B2 · Fung et al. · 2014 [cited by applicant]
US 9067994B2 · Fung et al. · 2015 [cited by applicant]
US 9605065B2 · Fung et al. · 2017 [cited by applicant]
US 9920120B2 · Yu et al. · 2018 [cited by applicant]
US 10000562B2 · Deshmukh et al. · 2018 [cited by applicant]
US 10093730B2 · Hass et al. · 2018 [cited by applicant]
US 10112994B2 · Giulianotti et al. · 2018 [cited by applicant]
US 10597446B2 · Yu et al. · 2020 [cited by applicant]
US 10597447B2 · Yu et al. · 2020 [cited by applicant]
US 10683348B2 · Fuh et al. · 2020 [cited by applicant]
US 10723795B2 · Hass et al. · 2020 [cited by applicant]
US 10738131B2 · Chen et al. · 2020 [cited by applicant]
US 10752703B2 · Chen et al. · 2020 [cited by applicant]
US 10882922B2 · Yang et al. · 2021 [cited by applicant]
US 10947307B2 · Deshmukh et al. · 2021 [cited by applicant]
US 11192960B2 · Yang et al. · 2021 [cited by applicant]
US 11226341B2 · Arron et al. · 2022 [cited by applicant]
US 11299539B2 · Giulianotti et al. · 2022 [cited by applicant]
US 11434286B2 · Lin et al. · 2022 [cited by applicant]
US 11434287B2 · Fung et al. · 2022 [cited by applicant]
US 11453727B2 · Rao et al. · 2022 [cited by applicant]
US 11725050B2 · Hass et al. · 2023 [cited by applicant]
US 11754573B2 · Morgan et al. · 2023 [cited by applicant]
US 11827671B2 · Soubrane et al. · 2023 [cited by applicant]
US 11840566B2 · Rommelaere et al. · 2023 [cited by applicant]
US 11891437B2 · Famili et al. · 2024 [cited by applicant]
US 20030031666A1 · Debinski et al. · 2003 [cited by applicant]
US 20060063228A1 · Kasaian et al. · 2006 [cited by applicant]
US 20070292442A1 · Wan et al. · 2007 [cited by applicant]
US 20090098142A1 · Kasaian et al. · 2009 [cited by applicant]
US 20100129360A1 · Kasaian et al. · 2010 [cited by applicant]
US 20140044645A1 · Arron · 2014 [cited by examiner]
US 20150225479A1 · Huille et al. · 2015 [cited by applicant]
US 20160207995A1 · Yansura et al. · 2016 [cited by applicant]
US 20160230226A1 · Abbas et al. · 2016 [cited by applicant]
US 20160272706A1 · Carmen · 2016 [cited by examiner]
US 20160363591A1 · Streicher et al. · 2016 [cited by applicant]
US 20170067108A1 · Abbas et al. · 2017 [cited by applicant]
US 20170298119A1 · Wollacott · 2017 [cited by examiner]
US 20170334985A1 · Wu et al. · 2017 [cited by applicant]
US 20180251538A1 · Fung et al. · 2018 [cited by applicant]
US 20180356429A1 · Morimoto et al. · 2018 [cited by applicant]
US 20190002552A1 · Deshmukh · 2019 [cited by examiner]
US 20190024178A1 · Abbas et al. · 2019 [cited by applicant]
US 20190062836A1 · Abbas et al. · 2019 [cited by applicant]
US 20200165679A1 · Abbas et al. · 2020 [cited by applicant]
US 20210115124A1 · Koenig et al. · 2021 [cited by applicant]
US 20210155684A1 · Deshmukh et al. · 2021 [cited by applicant]
US 20210188965A1 · Rommelaere et al. · 2021 [cited by applicant]
US 20210261649A1 · Parry et al. · 2021 [cited by applicant]
US 20220033520A1 · Lazar et al. · 2022 [cited by applicant]
US 20220089728A1 · Degenhardt et al. · 2022 [cited by applicant]
US 20220153854A1 · Rommelaere et al. · 2022 [cited by applicant]
US 20220177564A1 · Rommelaere et al. · 2022 [cited by applicant]
US 20220177566A1 · Rommelaere et al. · 2022 [cited by applicant]
US 20220228107A1 · Smith et al. · 2022 [cited by applicant]
US 20220275102A1 · Cameron et al. · 2022 [cited by applicant]
US 20220372131A1 · Lin et al. · 2022 [cited by applicant]
US 20220389449A1 · Paul et al. · 2022 [cited by applicant]
US 20230235088A1 · Rao et al. · 2023 [cited by applicant]
US 20230250165A1 · Yu et al. · 2023 [cited by applicant]
US 20230357381A1 · Bardroff et al. · 2023 [cited by applicant]
US 20240101675A1 · Demishtein et al. · 2024 [cited by applicant]
US 20240117030A1 · Agostinelli et al. · 2024 [cited by applicant]
EP 1703893B1 · 2012 [cited by applicant]
EP 1711528B1 · 2012 [cited by applicant]
EP 2332575B1 · 2014 [cited by applicant]
EP 3060685B1 · 2019 [cited by applicant]
EP 2805728B1 · 2020 [cited by applicant]
EP 3218403B1 · 2020 [cited by applicant]
EP 3091029B1 · 2022 [cited by applicant]
EP 3528838B1 · 2023 [cited by applicant]
EP 3443006B1 · 2023 [cited by applicant]
EP 3718564B1 · 2023 [cited by applicant]
EP 3083682B1 · 2024 [cited by applicant]
WO 2005062967A2 · 2005 [cited by applicant]
WO 2008140455A1 · 2008 [cited by applicant]
WO 2015038888A1 · 2015 [cited by applicant]
WO 2017011773A2 · 2017 [cited by applicant]
WO 2018220216A1 · 2018 [cited by applicant]
WO 2021021676A1 · 2021 [cited by applicant]
WO 2022097060A1 · 2022 [cited by applicant]
WO 2023287590A1 · 2023 [cited by applicant]
WO 2023019260A1 · 2023 [cited by applicant]
WO 2023044313A1 · 2023 [cited by applicant]
WO 2023215769A1 · 2023 [cited by applicant]
WO 2023245187A2 · 2023 [cited by applicant]
WO 2024227141A1 · 2024 [cited by applicant]
Dall'Acqua WF, et al., “Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn),” J Biol Chem., vol. 281(33):23514-23524 (2006). [cited by applicant]
Deuschl, F. et al., “Molecular characterization of the hypothetical 66.3-kDa protein in mouse: Lyso-somal targeting, glycosylation, processing and tissue distribution,” FEBS Letters, vol. 580: 5747-5752 (2006). [cited by applicant]
Dumet, C. et al., “Insights into the IgG heavy chain engineering patent landscape as applied to IgG4 antibody development,” Mabs, vol. 11(8):1341-1350 (2019) doi: 10.1080/19420862.2019.1664365. [cited by applicant]
Gutierrez, A. et al., “Of 'hamsters and men: A new perspective on host cell proteins,” Human Vac-cines, vol. 8 (9): 1172-1174 (2012). [cited by applicant]
Hammitt LL, et al. “Nirsevimab for prevention of RSV in healthy late-preterm and term infants,” N Engl J Med., vol. 386(9):837-846 (2022). [cited by applicant]
Hezareh M, et al., “Effector function activities of a panel of mutants of a broadly neutralizing anti-body against human immunodeficiency virus type 1,” J Virol., vol. 75(24):12161-12168 (2001) doi:10.1128/JVI.75.24.121… [cited by applicant]
International Preliminary Report on Patentability, PCT/US2023/068621, dated Dec. 10, 2024, 9 pages. [cited by applicant]
International Search Report and Written Opinion, PCT/US2023/068621, dated Jun. 11, 2024, 13 pages. [cited by applicant]
Kato Y, et al., “Hydrophobic interaction chromatography at low salt concentration for the capture of monoclonal antibodies,” J Chromatogr., vol. 1036:45-50 (2004). [cited by applicant]
Liu et al., “Recovery and purification process development for monoclonal antibody production,” mAbs, vol. 2 (5): 480-499 (2010). [cited by applicant]
Lytvyn, Y. et al., “Targeting Interleukin 13 for the Treatment of Atopic Dermatitis,” Pharmaceutics, vol. 15(2):568 doi: 10.3390/pharmaceutics15020568 (2023). [cited by applicant]
NCT04718103, “A Study of GSK3511294 (Depemokimab) in Participants With Severe Asthma With an Eosinophilic Phenotype (SWIFT-2)” 2 pages. [cited by applicant]
Ortega H, et al., “Pharmacokinetics and absolute bioavailability of mepolizumab following administration at subcutaneous and intramuscular sites,” Clin Pharmacol Drug Dev., vol. 3(1):57-62 (2014). doi:10.1002/cpdd.60. [cited by applicant]
Ridker PM, et al., “IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RES-CUE): a double-blind, randomised, placebo-controlled, phase 2 trial,” Lancet, vol. 397(10289):2060-2069 (2021) doi:10.1… [cited by applicant]
Robbie GJ, et al., “A novel investigational Fc-modified humanized monoclonal antibody, motavi-zumab-YTE, has an extended half-life in healthy adults,” Antimicrob Agents Chemother., vol. 57(12):6147-6153 (2013) doi: 10.1… [cited by applicant]
Robbie GJ, et al., “Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncyt-ial virus monoclonal antibody, in adults and children,” Antimicrob Agents Chemother., vol. 56(9):4927-4936 (2012). doi:… [cited by applicant]
Rocca A, et al. “Passive immunoprophylaxis against respiratory syncytial virus in children: where are we now?” Int J Mol Sci., vol. 22(7):3703 (2021) doi:10.3390/ijms22073703. [cited by applicant]
Saunders KO, “Conceptual approaches to modulating antibody effector functions and circulation half-life,” Front Immunol., vol. 10:1296 (2019) doi:10.3389/fimmu.2019.01296. [cited by applicant]
Shukla, A. et al., “Downstream processing of monoclonal antibodies-application of platform approaches,” J. Chromatogr., 28-39 (2007). [cited by applicant]
Singh D, et al., “A Phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in pa-tients with asthma,” Br J Clin Pharmacol., vol. 88(2):702-712 (2022). [cited by applicant]
Vanderlaan, Martin et al., “Hamster phospholipase B-like 2 (PLBL2): A host-cell protein impurity in therapeutic monoclonal antibodies derived from Chinese hamster ovary cells,” BioProcess Interna-tional, vol. 13. (2015). [cited by applicant]
Wines BD, et al., “The IgG Fc contains distinct Fc receptor (FcR) binding sites: the leukocyte recep-tors Fc gamma RI and Fc gamma Rlla bind to a region in the Fc distinct from that recognized by neo-natal FcR and prote… [cited by applicant]